相似文献
1
FLT3 inhibitors for the treatment of autoimmune disease.
Expert Opin Investig Drugs. 2008 Nov;17(11):1685-92. doi: 10.1517/13543784.17.11.1685.
2
Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease.
Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16741-6. doi: 10.1073/pnas.0506088102. Epub 2005 Nov 4.
3
FLT3 signaling and the development of inhibitors that target FLT3 kinase activity.
Crit Rev Oncog. 2012;17(2):199-209. doi: 10.1615/critrevoncog.v17.i2.50.
4
Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia.
J Med Chem. 2020 Nov 12;63(21):12403-12428. doi: 10.1021/acs.jmedchem.0c00696. Epub 2020 Jul 21.
5
Emerging Flt3 kinase inhibitors in the treatment of leukaemia.
Expert Opin Emerg Drugs. 2006 Mar;11(1):153-65. doi: 10.1517/14728214.11.1.153.
6
Discovery of N-(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid Leukemia.
J Med Chem. 2019 Jan 24;62(2):875-892. doi: 10.1021/acs.jmedchem.8b01594. Epub 2019 Jan 8.
7
The Future of Targeting FLT3 Activation in AML.
Curr Hematol Malig Rep. 2017 Jun;12(3):153-167. doi: 10.1007/s11899-017-0381-2.
8
Accumulation of FLT3(+) CD11c (+) dendritic cells in psoriatic lesions and the anti-psoriatic effect of a selective FLT3 inhibitor.
Immunol Res. 2014 Oct;60(1):112-26. doi: 10.1007/s12026-014-8521-4.
9
The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias.
Pharmacol Res. 2020 May;155:104725. doi: 10.1016/j.phrs.2020.104725. Epub 2020 Feb 25.
10
Studies on the anti-psoriasis effects and its mechanism of a dual JAK2/FLT3 inhibitor flonoltinib maleate.
Biomed Pharmacother. 2021 May;137:111373. doi: 10.1016/j.biopha.2021.111373. Epub 2021 Feb 24.
引用本文的文献
1
A germline FLT3 variant in aplastic anemia.
Biomark Res. 2025 Jan 7;13(1):4. doi: 10.1186/s40364-024-00717-3.
2
Molecular Landscape of Tourette's Disorder.
Int J Mol Sci. 2023 Jan 11;24(2):1428. doi: 10.3390/ijms24021428.
3
Molecular Taxonomy of Systemic Lupus Erythematosus Through Data-Driven Patient Stratification: Molecular Endotypes and Cluster-Tailored Drugs.
Front Immunol. 2022 May 9;13:860726. doi: 10.3389/fimmu.2022.860726. eCollection 2022.
4
Synthesis and In-Vivo Evaluation of Benzoxazole Derivatives as Promising Anti-Psoriatic Drugs for Clinical Use.
Molecules. 2022 May 8;27(9):3023. doi: 10.3390/molecules27093023.
5
Transcriptome-wide association study reveals increased neuronal FLT3 expression is associated with Tourette's syndrome.
Commun Biol. 2022 Mar 30;5(1):289. doi: 10.1038/s42003-022-03231-0.
6
Peel Polysaccharides Ameliorate Imiquimod-Induced Psoriasis-Like Dermatitis in Mice Suppression of NF-κB and STAT3 Pathways.
Front Pharmacol. 2022 Jan 28;12:806844. doi: 10.3389/fphar.2021.806844. eCollection 2021.
7
Aptamer-based search for correlates of plasma and serum water T: implications for early metabolic dysregulation and metabolic syndrome.
Biomark Res. 2018 Sep 17;6:28. doi: 10.1186/s40364-018-0143-x. eCollection 2018.
8
Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia.
Leukemia. 2018 Feb;32(2):313-322. doi: 10.1038/leu.2017.257. Epub 2017 Aug 14.
9
The origin of DCs and capacity for immunologic tolerance in central and peripheral tissues.
Semin Immunopathol. 2017 Feb;39(2):137-152. doi: 10.1007/s00281-016-0602-0. Epub 2016 Nov 25.
10
Accumulation of FLT3(+) CD11c (+) dendritic cells in psoriatic lesions and the anti-psoriatic effect of a selective FLT3 inhibitor.
Immunol Res. 2014 Oct;60(1):112-26. doi: 10.1007/s12026-014-8521-4.
本文引用的文献
1
Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial.
Arch Dermatol. 2008 Feb;144(2):200-7. doi: 10.1001/archdermatol.2007.63.
2
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
J Natl Cancer Inst. 2008 Feb 6;100(3):184-98. doi: 10.1093/jnci/djm328. Epub 2008 Jan 29.
3
Etanercept treatment for children and adolescents with plaque psoriasis.
N Engl J Med. 2008 Jan 17;358(3):241-51. doi: 10.1056/NEJMoa066886.
4
T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma.
Immunity. 2008 Jan;28(1):29-39. doi: 10.1016/j.immuni.2007.11.016. Epub 2007 Dec 27.
5
Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis.
Ann Rheum Dis. 2008 Sep;67(9):1299-304. doi: 10.1136/ard.2007.080341. Epub 2007 Dec 6.
6
Type I interferons inhibition of inflammatory T helper cell responses in systemic lupus erythematosus.
Ann N Y Acad Sci. 2007 Jun;1108:11-23. doi: 10.1196/annals.1422.002.
7
IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells.
Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12099-104. doi: 10.1073/pnas.0705268104. Epub 2007 Jul 10.
8
TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1.
Nat Med. 2007 Jun;13(6):711-8. doi: 10.1038/nm1585. Epub 2007 May 13.
9
Efficacy and safety of etanercept in psoriasis/psoriatic arthritis: an updated review.
Am J Clin Dermatol. 2007;8(3):143-55. doi: 10.2165/00128071-200708030-00002.
10
Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
Gastroenterology. 2007 May;132(5):1672-83. doi: 10.1053/j.gastro.2007.03.024. Epub 2007 Mar 21.
Zotero 插件